Volume | 385,765 |
|
|||||
News | - | ||||||
Day High | 2.93 | Low High |
|||||
Day Low | 2.801 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Poseida Therapeutics Inc | PSTX | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
2.85 | 2.801 | 2.93 | 2.92 | 2.83 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
3,773 | 385,765 | $ 2.85 | $ 1,098,791 | - | 1.54 - 4.27 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
18:16:56 | 1 | $ 2.90 | USD |
Poseida Therapeutics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
282.71M | 96.49M | - | 64.7M | -123.43M | -1.28 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Poseida Therapeutics News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical PSTX Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 2.29 | 3.00 | 2.27 | 2.76 | 1,173,574 | 0.61 | 26.64% |
1 Month | 2.99 | 3.02 | 1.91 | 2.47 | 685,256 | -0.09 | -3.01% |
3 Months | 3.61 | 4.27 | 1.91 | 3.10 | 719,886 | -0.71 | -19.67% |
6 Months | 2.39 | 4.27 | 1.91 | 3.05 | 829,969 | 0.51 | 21.34% |
1 Year | 3.31 | 4.27 | 1.54 | 2.63 | 832,331 | -0.41 | -12.39% |
3 Years | 8.32 | 11.10 | 1.54 | 3.82 | 586,103 | -5.42 | -65.14% |
5 Years | 17.00 | 17.62 | 1.54 | 4.84 | 533,287 | -14.10 | -82.94% |
Poseida Therapeutics Description
Poseida Therapeutics Inc is a clinical-stage biopharmaceutical company focused on leveraging non-viral gene engineering technologies to create life-saving therapeutics for patients with a high unmet delivery technology. It has built a pipeline of autologous and allogeneic chimeric antigen receptor T cell, or CAR-T, product candidates, initially focused on the treatment of hematological malignancies and solid tumours. |